Please find attached transcript of the Investor Conference Call held on May 20, 2026
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mankind Pharma reported Q4 FY26 revenue of INR 3,443 crores (11.8% YoY) with adjusted EBITDA margin of 27.1%, significantly improved from 23.1% in Q4 FY25. Full year FY26 revenue was INR 14,278 crores (17% YoY) with EBITDA margin of 25.4%. PAT grew 30.4% YoY to INR 559 crores in Q4. The company acquired Rivotril brand from Roche and launched GLP-1 pen. Net debt stands at INR 3,932 crores with net debt/EBITDA at 1.1x, on track to repay acquisition debt by FY28. Volume growth improved to 2.3% from 0.5% last year, with chronic therapy now contributing ~40% of sales. Management guided FY27 EBITDA margin at 25.5%-26.5% with better-than-FY26 topline growth.
Strong Q4 margin recovery to 27.1% demonstrates operational improvement. Management's FY27 guidance of double-digit growth and 25.5-26.5% EBITDA margin is positive for shareholders. Debt reduction on track with INR 1,250 crore repayment completed in April 2026.